Cargando…

PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients

Detalles Bibliográficos
Autores principales:	Hofer, F, Endres, T, Kortus-Götze, B, Blank, N, Weißbarth-Riedel, E, Schütz, C, Kallinich, T, Krause, K, Rietschel, C, Horneff, G, Kuemmerle-Deschner, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043406/ http://dx.doi.org/10.1186/1546-0096-11-S2-P214

Ejemplares similares

PW02-041 - Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

Canakinumab treat-to target strategies increase complete response rate in CAPS
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

PReS-FINAL-2331: Low-penetrance NLRP3 variants
por: Endres, T, et al.
Publicado: (2013)

Pharmacokinetics of Canakinumab in children younger than 2 years old with CAPS
por: Kalabus, J, et al.
Publicado: (2015)

Efficacy, safety, and post-vaccination antibody titer data in children with CAPS treated with Canakinumab
por: Brogan, P, et al.
Publicado: (2015)

PW02-040 - Low-penetrance NLRP3 variants
por: Endres, T, et al.
Publicado: (2013)

PReS-FINAL-2330: Canakinumab treatment in patients with HIDS
por: Antón, J, et al.
Publicado: (2013)

Rapid and Sustained Long‐Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin‐Associated Periodic Syndrome Ages Five Years and Younger
por: Brogan, Paul A., et al.
Publicado: (2019)

PReS-FINAL-2157: Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis
por: Quartier, P, et al.
Publicado: (2013)

Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

A refractory heterogeneous Cryopyrin-Associated Periodic Syndrome (CAPS) phenotype related to V198M mutation responds to canakinumab - a case report
por: Hansmann, Sandra, et al.
Publicado: (2011)

Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients
por: Bader-Meunier, B, et al.
Publicado: (2011)

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)
por: Kuemmerle-Deschner, Jasmin B, et al.
Publicado: (2011)

Treatment of systemic-onset juvenile arthritis with canakinumab
por: Peitz, Joachim, et al.
Publicado: (2015)

PReS-FINAL-2329: Validation of the autoinflammatory activity index (AIDAI)
por: Piram, M, et al.
Publicado: (2013)

PReS-FINAL-2169: Exposure-response modeling of canakinumab in the avoidance of flares in children with systemic juvenile idiopathic arthritis
por: Xiong, Y, et al.
Publicado: (2013)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015)

PReS-FINAL-2337: The eurofever registry: 3 years of enrollment
por: Federici, S, et al.
Publicado: (2013)

P02-027 - Quality of life in CAPS treated by Canakinumab
por: Marsaud, C, et al.
Publicado: (2013)

PReS-FINAL-2194: Evidence-based clinical classification criteria for periodic fevers
por: Federici, S, et al.
Publicado: (2013)

PReS-FINAL-2156: Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapy
por: Nirmala, N, et al.
Publicado: (2013)

12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)
por: Kümmerle-Deschner, J, et al.
Publicado: (2008)

Unmet psychosocial needs in CAPS
por: Erbis, G, et al.
Publicado: (2015)

Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry
por: Raab, A., et al.
Publicado: (2021)

Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today?
por: Welzel, Tatjana, et al.
Publicado: (2021)

PReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients
por: Quartier, P, et al.
Publicado: (2013)

PReS-FINAL-2216: Biomarkers MRP8/14 and S100A12 correspond with flare and remission clinical status in Sojia patients in the AID-NET register
por: Gohar, F, et al.
Publicado: (2013)

2224. Aminopenicillins versus Non-aminopenicillins for Treatment of Enterococcal Cystitis
por: de Oca, Jamison Montes, et al.
Publicado: (2022)

The phagocyte specific protein S100A12 as a novel biomarker in Muckle-Wells-Syndrome before and during therapy with Anakinra and Canakinumab (ACZ885)
por: Wittkowski, H, et al.
Publicado: (2008)

PReS-FINAL-2336: Induction of MDSCS in Muckle-Wells syndrome
por: Rieber, N, et al.
Publicado: (2013)

Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry
por: Walker, Ulrich A, et al.
Publicado: (2021)

Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
por: Toker, Ori, et al.
Publicado: (2010)

PReS-FINAL-2215: Genotype-phenotype correlations in children with Familial Mediterranean Fever in Germany
por: Gohar, F, et al.
Publicado: (2013)

PReS-FINAL-2179: Efficacy and safety of adalimumab in pediatric patients with enthesitis related arthritis
por: Burgos-Vargas, R, et al.
Publicado: (2013)

An experience of use of canakinumab IL-1 inhibitor in children with cryopyrin-associated periodic syndromes (CAPS)
por: Salugina, Svetlana O, et al.
Publicado: (2014)

PReS-FINAL-2152: Biomarkers as predictors of early inactive disease in children with juvenile idiopathic arthritis
por: Lavric, M, et al.
Publicado: (2013)

Consensus protocols for the diagnosis and management of the hereditary autoinflammatory syndromes CAPS, TRAPS and MKD/HIDS: a German PRO-KIND initiative
por: Hansmann, Sandra, et al.
Publicado: (2020)

2224: Characterizing vigilant thoughts and behaviors that disrupt sleep in veterans and utilization of cognitive techniques
por: Katherine Howell, Mary, et al.
Publicado: (2018)

PReS-FINAL-2217: Atypical presentation of CRMO in two children
por: Vanoni, F, et al.
Publicado: (2013)

Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
por: Caorsi, R, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_aod67uh34vgk31ucuguniektvh